Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Early research (Phase 1)UnknownNCT03026881
What this trial is testing

Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Who this might be right for
Recurrent and Metastatic Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd. 24
Large-scale testing (Phase 3)Ended earlyNCT01905592
What this trial is testing

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Neoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast+3 more
Tesaro, Inc. 216
Testing effectiveness (Phase 2)UnknownNCT04734665
What this trial is testing

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Who this might be right for
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Yonsei University 44
Testing effectiveness (Phase 2)Looking for participantsNCT06747845
What this trial is testing

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Who this might be right for
Pancreatic Adenocarcinoma Metastatic
Abramson Cancer Center at Penn Medicine 68
Not applicableLooking for participantsNCT06785077
What this trial is testing

Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

Who this might be right for
Leukemia, Myeloid, AcuteMyeloid DysplasiaOvarian Epithelial Cancer
European Institute of Oncology 157
Testing effectiveness (Phase 2)Study completedNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Testing effectiveness (Phase 2)Study completedNCT00494442
What this trial is testing

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasm
AstraZeneca 58
Not applicableUnknownNCT04675320
What this trial is testing

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

Who this might be right for
Ovarian Cancer
Centre Georges Francois Leclerc 50
Large-scale testing (Phase 3)Active Not RecruitingNCT04380636
What this trial is testing

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 870
Large-scale testing (Phase 3)Ended earlyNCT02470585
What this trial is testing

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerOvarian Neoplasm
AbbVie 1,140
Testing effectiveness (Phase 2)UnknownNCT06161272
What this trial is testing

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
Guangxi Medical University 80
Testing effectiveness (Phase 2)Study completedNCT01078662
What this trial is testing

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Who this might be right for
OvarianBreastProstate+2 more
AstraZeneca 298
Not applicableStudy completedNCT02262273
What this trial is testing

OSCA - Olaparib Standard of CAre Study

Who this might be right for
Platinum-sensitive Recurrent Serous Ovarian Cancer
AstraZeneca 2,123
Early research (Phase 1)Study completedNCT01286987
What this trial is testing

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Who this might be right for
Advanced or Recurrent Solid TumorsBreast NeoplasmsOvarian Cancer, Epithelial+4 more
Pfizer 113
Early research (Phase 1)WithdrawnNCT04149145
What this trial is testing

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer Recurrent
University of Alabama at Birmingham
Testing effectiveness (Phase 2)Ended earlyNCT02326844
What this trial is testing

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 3
Early research (Phase 1)Looking for participantsNCT07382544
What this trial is testing

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Who this might be right for
Advanced CancerSolid Tumor
M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)WithdrawnNCT04239014
What this trial is testing

Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Who this might be right for
Ovarian Cancer
AstraZeneca
Testing effectiveness (Phase 2)WithdrawnNCT03044795
What this trial is testing

Response to PARP Inhibitor Predicted by the RAD51 Assay

Who this might be right for
Cancer
University Medical Center Groningen
Next Page